IN8bio, Inc. (NASDAQ:INAB – Get Free Report) saw a significant drop in short interest in October. As of October 30th, there was short interest totaling 15,733 shares, a drop of 52.0% from the October 15th total of 32,797 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average trading volume of 36,207 shares, the short-interest ratio is currently 0.4 days.
IN8bio Stock Down 0.0%
INAB traded down $0.00 during trading on Friday, reaching $0.82. The company had a trading volume of 7,622 shares, compared to its average volume of 35,660. The stock has a market cap of $8.86 million, a P/E ratio of -0.81 and a beta of 0.27. The business has a 50 day simple moving average of $1.10 and a 200-day simple moving average of $1.39. IN8bio has a 52 week low of $0.80 and a 52 week high of $2.73.
IN8bio (NASDAQ:INAB – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.10. As a group, equities research analysts expect that IN8bio will post -1.49 EPS for the current fiscal year.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of IN8bio in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.
Read Our Latest Stock Report on IN8bio
IN8bio Company Profile
IN8bio is a clinical-stage biopharmaceutical company developing ?? T cell therapeutic and ?? T cell engager (TCE) product candidates to address unmet medical needs. ?? T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic ?? T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation.
Featured Stories
- Five stocks we like better than IN8bio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.
